http://www.bing.com:80/search?q=Simple+Graph+TransformationsSearch resultshttp://www.bing.com:80/s/a/rsslogo.gifhttp://www.bing.com:80/search?q=Simple+Graph+TransformationsCopyright © 2026 Microsoft. All rights reserved. These XML results may not be used, reproduced or transmitted in any manner or for any purpose other than rendering Bing results within an RSS aggregator for your personal, non-commercial use. Any other use of these results requires express written permission from Microsoft Corporation. By accessing this web page or using these results in any manner whatsoever, you agree to be bound by the foregoing restrictions.https://clinicaltrials.gov/study/NCT07464314This early-stage study will look at a new mRNA vaccine that combines defenses against both seasonal flu and COVID-19 in terms of its safety and how it builds protection.Thu, 04 Jun 2026 08:34:00 GMThttps://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/adults.htmlThere are three FDA-licensed RSV vaccines recommended for use in adults ages 50 and older: GSK’s Arexvy, Moderna’s mResvia, and Pfizer’s Abrysvo. There is no preference for which vaccine adults 50 and older should receive.Mon, 08 Jun 2026 02:46:00 GMThttps://pubmed.ncbi.nlm.nih.gov/41450594/Two RSV prefusion F protein (RSVpreF) vaccines currently are approved for adults aged 60 years and older. However, little is known about the adverse events reported among individuals in this age group who have received an RSVpreF vaccine.Thu, 07 May 2026 00:32:00 GMThttps://www.gsk.com/en-gb/media/press-releases/gsk-s-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows/GSK plc (LSE/NYSE: GSK) today announced new effectiveness data for its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine at RSVVW’26, the 9th Conference of the Respiratory Syncytial Virus Foundation (ReSViNET) in Rome, Italy.Sat, 06 Jun 2026 01:01:00 GMThttps://www.fda.gov/vaccines-blood-biologics/industry-biologics/covid-19-vaccines-2026-2027-formula-use-united-states-beginning-fall-2026FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) met on May 28, 2026, to discuss and make recommendations on the selection of the 2026-2027 Formula for COVID-19...Tue, 02 Jun 2026 16:15:00 GMThttps://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-updated-guidance-respiratory-syncytial-virus-vaccines-older-adults-high-risk-severe-rsv-disease.htmlThere are now three vaccines available to protect older adults and adults at high risk of severe disease from RSV in Canada: RSVPreF3 (AREXVY, GSK) is authorized to protect individuals 60 years of age and older, and individuals 50 to 59 years of age at increased risk of RSV disease.Thu, 09 Apr 2026 23:53:00 GMThttps://clinicaltrials.gov/study/NCT07117487?a=2The purpose of this study is to evaluate safety, tolerability and immunogenicity of mRNA-1345 in participants who have been previously vaccinated with either Arexvy or Abrysvo at least 12 months prior to enrollment, are medically stable and aged ≥60 years.Sat, 28 Feb 2026 18:06:00 GMThttps://www.gsk.com/en-gb/media/press-releases/Pivotal B-Well data show a significant 19% functional cure in the overall study population and 26% in patients with lower viral activity. GSK will present new data from its expanding oncology portfolio and pipeline at ASCO and EHA.Mon, 08 Jun 2026 02:46:00 GMThttps://pubmed.ncbi.nlm.nih.gov/41746067/We evaluated immunogenicity and safety when ExPEC9V was co-administered with high-dose (HD) quadrivalent seasonal influenza vaccine.Fri, 22 May 2026 05:08:00 GMThttps://www.cdc.gov/respiratory-viruses/data/vaccination-trends.htmlCDC recommends COVID-19 vaccines for people ages 6 months and older, with discussion of the benefits of vaccination with a health care provider. The FDA authorized the COVID-19 vaccines for the 2025-26 fall and winter virus season in August 2025.Sun, 07 Jun 2026 21:31:00 GMT